AVI BioPharma appoints new senior VP and CFO
This article was originally published in Scrip
Executive Summary
AVI BioPharma(US), a developer of RNA-based drugs, has appointed David Boyle senior vice-president and chief financial officer. Mr Boyle is expected to join the company on August 18th, at which time, Mark Webber, the company's current CFO, will assume a new position within AVI as general manager of finance and administration. Mr Boyle was previously vice-president of finance and chief financial officer at Xoma.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.